anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine, ophthalmology, pharmacy. SUBSTANCE: invention proposes irrigative composition &#34;Gidroelastic&#34; for an intraocular application containing sodium chloride and water and, additionally, sodium buffer salts and water-soluble polymers taken in the following ratio of components, wt.-%: sodium chloride, 0.138-0.164 M; sodium buffer salts, 0.001-0.030 M; water-soluble polymers, 0.020-20.0; water, the balance, with pH value from 6.8 to 7.6 and viscosity value from 3 to 600 sSt. One variant of invention involves irrigative composition &#34;Gidroelastic&#34; for intraocular application comprises additionally medicinal agent and another variant involves irrigative composition with additional content of metal ions that are necessary for normal maintenance of metabolic processes in intraocular fluid. Invention provides reduction of irrigative trauma in surgery operations and, therefore, reduction of time for visual rehabilitation of patient after operation. EFFECT: enhanced effectiveness and valuable medicinal properties of composition. 3 cl, 3 ex
The invention provides methods and means for enhancing the epidermal, transdermal and dermal permeation of a topically applied pharmacologically active agent (e.g., a drug or medicament) which has a low rate of skin penetration in the absence of a permeation enhancer and which is unstable and degrades during long-term storage with particular permeation enhancers. Also provided by the invention are methods and means to increase the skin penetration of a pharmacologically active agent which has a normally low rate of skin permeation and causes the instability and degradation of a permeation enhancer with which it is combined over a long period of time. Provided by the invention are at least one first composition containing a drug, a pharmaceutically acceptable salt, chemical derivative or formulation thereof, in a dermatologically acceptable vehicle, and at least one second composition containing a permeation enhancer in an acceptable vehicle. The compositions are physically separated until application to a body or skin surface and are topically applied, either at the same time, or sequentially within a short time of each other, and mixed or blended to form a final active composition, preferably on the skin. In addition, a premixture of the compositions can be made and applied to the skin in accordance with the invention. The invention allows a therapeutically effective amount of drug to be delivered into the skin and systemic circulation and provides significant enhancement of a drug&#39;s otherwise low level of skin permeation by the action of permeation enhancer in the active composition at the point of use.
Disclosed are a 1,2,3-tricarballylic acid coupled EPO peptoid derivative and a preparation method and application thereof. The invention relates to a 1,2,3-tricarballylic acid coupled erythropoietin (EPO) peptoid derivative and a dimer thereof. The peptoid derivative is monomer peptide having a sequence shown as SEQ ID NO:1 of GGLYAC6HMGPITX&lt;1&gt;VC15QPLRX&lt;2&gt;K, wherein X&lt;1&gt; is 3-(1-naphthyl)-L-alanine (Na1), X&lt;2&gt; is sarcosine (Sar), cysteine (C) at the sixth site and the fifteenth site forms an intramolecular disulfide bond, and the N terminal is acetylized. The general formula of the dimer is shown as the formula I in the description. The invention further provides a preparation method and pharmaceutically-acceptable salt of the peptoid derivative and the dimer. The invention further provides a pharmaceutical composition containing the peptoid derivative or the dimer or pharmaceutically-acceptable salt thereof. The EPO peptoid derivative, the dimer and the pharmaceutically-acceptable salt thereof can stimulate erythropoiesis and obviously prolong the half-life period of the medicine in the body.
This invention relates to a method and system that identifies pass-through items, medications and/or sub-procedures that are typically associated with the performance of medical procedures yet not listed on corresponding medical claim records. The invention includes the steps of storing a database of medical records on a first computer data storage medium, storing a database of event codes on a second computer data storage medium, and electronically transmitting the database of records to the second computer data storage medium. Each event code corresponds to a pass-through item, medication or sub-procedure. The invention analyzes a particular medical procedure and determines if an event code should be listed on the record corresponding to that particular medical procedure. If not, the invention transmits a report identifying the missing event code, and in one embodiment, generates a new record with the proper event code now properly listed. The transfer of claim record information, and any subsequent reports listing omitted event codes can be performed either automatically or at the user&#39;s request, via an intranet or Internet connection and allows the user to quickly determine which medical procedures listed in the claim records have omitted associated medical devices or sub-procedures, which, if listed, would be reimbursable to the medical facility.
PURPOSE:To obtain water- and oil-repellent powder for cosmetics excellent in water and oil repellency and touch after use, especially smoothness by treating the surface of powder with alcohol having a perfluoroalkyl group contg. a specified number of C atoms and a compd. having a perfluoroalkyl group contg. a specified number or more of C atoms and other than the alcohol. CONSTITUTION:The surface of powder is treated with fluorinated alcohol represented by a formula Rf&lt;1&gt;(CH2)mO(AO)nH and a compd. having a straight or branched chain &gt;=6C perfluoroalkyl group or a group obtd. by substituting H for one of the F atoms of the perfluoroalkyl group in the molecule and other than the fluorinated alcohol to obtain the objective water- and oil-repellent powder. In the formula, Rf&lt;1&gt; is a straight or branched chain 3-12C perfluoroalkyl group or a group obtd. by substituting H for one of the F atoms of the perfluoroalkyl group, A is 2-3C alkylene, m is a number of 0-12, n is a number of 0-10, and in the case of n&gt;=2, two or more A&#39;s may be different from each other.
A vaccine against canine distemper is produced by cultivating canine distemper virus in at least 50 successive changes of a culture tissue obtained from canid  or mustelid  while using a buffered nutrient fluid at pH 7.0 to 8.0 and harvesting the attenuated virus-containing nutrient fluid thus obtained.  The culture tissue may be kidney, spleen, testicles or uterus of canid  or musteld .  Stationary monolayer cultures of trypsinized tissue are used in (a) Hank&#39;s solution containing 0.5% lactalbumin hydrolysate with 10% horse serum or 20% calf serum or (b) Earle&#39;s solution containing 2% hourse serum and 0.5% lactalbumin hydrolysate, and also containing penicillin and streptomycin, the pH being adjusted to pH 7 to 8.  The culture fluid is harvested after 3 to 4 days by collecting the culture fluid which contains the virus.  The remaining cells may be used for repeated cultivations by addition of fresh nutrient medium to a total of four harvests of virus containing culture fluid.  The culture fluid containing the virus is used to inoculate fresh culture tissue. After 50 passages, the resultant culture fluid may be used directly as a vaccine or lyophilized until required for vaccination.
A mask includes a body having an interior surface defining a cavity shaped to receive a user&#39;s nose. An exterior surface of the body is exposed to an ambient environment. The body includes an inlet in fluid communication with the cavity and a one-way exhaust valve in fluid communication between the cavity and the ambient environment. A therapeutic substance dispenser is in fluid communication with the cavity. In one embodiment, a nasal aromatic decongestant is disposed in the therapeutic dispenser. A mask includes an upper nasal cavity separate from a lower oral cavity, with an inlet in fluid communication with only the upper nasal cavity. A medicament delivery assembly, and methods for the use thereof, are also provided.
NEW MATERIAL:A phospholipid derivative of formula I (R&lt;1&gt; is 8-30C aliphatic hydrocarbon residue; R&lt;2&gt;-R&lt;4&gt; are H, lower alkyl, etc.; n is 0 or 1) and a salt thereof. EXAMPLE:Tetradecyl-2-pyridinioethyl phosphate. USE:An antitumor agent, capable of exhibiting the direct cytotoxicity to tumorous cells and further host-induced antitumor effect, and having a life prolonging effect on patients with leukemia or solid cancers, e.g. cancer of the digestive organs or lung, and useful as an antifungal, agricultural germicide and antiprotozoal agent. PROCESS:A compound of the formula R&lt;1&gt;OH is reacted with a compound of formula II (X and Y are halogen) in an inert solvent, e.g. benzene or toluene, to give a compound of formula III, which is then hydrolyzed with water to afford a compound of formula IV. The resultant compound of formula IV is then reacted with a compound of formula V in an inert solvent to give the aimed compound of formula I (n is 1).
PURPOSE:To obtain the titled drug suitable as a medical preparation, by forming a thin membrane of lipid, adding calcium ion to the suspension of said membrane, freezing and thawing the mixture, and adding blood coagulation factor VIIIand a chelating agent to the product to form fat corpuscles. CONSTITUTION:Solvent is distilled off from a solution of a proper lipid to form a thin membrane of the lipid, which is suspended in a liquid, and added with calcium ion (final concentration of the ion is 10-30mM) to effect the coagulation of the membrane. The product is frozen, thawed, added with blood coagulation factor VIII (F-VIII) and then with a chelating agent (e.g. EDTA) to bond the calcium ion with chelate bond and to form fat corpuscles. Particles containing F-VIII and having diameter of about 0.01-1mu can be prepared by this process. Since the obtained F-VIII fat corpuscle preparation contains &gt;=0.5 unit of F-VIII per 1mg of phospholipid, and has uniform and small particle diameter, it is useful as a remedy for hemophilia A, etc.
A system and method for providing a computed radiography (CR) system customer with a recommended CR system and/or CR system configuration. The recommended CR system being established by a customer&#39;s responses to a plurality of questions. The system has a product selector file and a product configuration file. The product selector file provides a query page with the plurality of questions to be answered by the customer. The product configuration file having a plurality of predicted system values. A Java applet being used to compare the customer&#39;s responses to the plurality of questions to the predicted values. The product configuration file supplying a results page with the recommended system.
PURPOSE:To mold a powdered crude drug in a form of ready internal use without losing active ingredients, by pressurizing powdered Japanese or Chinese crude drug into a sheet form without adding water or an organic solvent, crushing and sizing the molded powder to a given size. CONSTITUTION:A Japanese or Chinese crude drug is cut to a size of about 1cm, put in a hermetically sealed container, frozen with injected liquid nitrogen and powdered in a pulverizer to provide a powdered Japanese or Chinese crude drug having 20-50mu size. The powder is then pressurized under 80-100kg/cm&lt;2&gt; pressure using a pressure roller and molded into a sheet form having 1.0-1.5mm thickness. In the process, pressurizing is carried out without using water or an organic solvent. The obtained sheet material is further crushed and sieved into granules having 30-150 mesh size or fine particles of 180-500mu size to afford the aimed substance. Essential oil ingredients or trace amounts of water in cells ooze out simply by pressurizing to provide a binder and molding can be carried out. Since water or organic solvent is not used, drying steps are omitted and crude drugs equal to those of original crude drugs are obtained without deterioration or denaturation.
A lotion suitable for use in the cold permanent waving of hair and in the straightening of hair comprises an aqueaus solution of a mercapton, e.g. a salt of thioglycollic such as ammonium thiogly collate, and 0.1 to 5.0% w/v of a salt of a hydrophilic coloidal acid, e.g. a salt formed from alginic acid, carboxy methyl cellulose or a carboxy polymethylene and an inorganic base, such as ammonia or sodium hydroxide, or an organic-base, such as monoethanolamine.  The salt of the colloid may be employed per se or may be formed in situ by incorporating the colloid into the lotion in conjunction with a base.  Hair may be waved by treating it with the lotion either before or after placing it in a desired configuration and then applying a neutraliser.  The hair may be simultaneously coloured and waved by incorporating a dyestuff which is dermatologically safe for use on the scalp into the lotion.  Suitable dyestuffs are preformed water soluble coal tar dyes of the acid level-dyeing type, water soluble oxidation dyestuffs, e.g. p-phenylene diamine, m-phenylenediamine, resorcinol and catechol, and basic dyestuffs if sufficiently soluble in water or a water-miscible solvent such as ethanol, e.g. Methylene Blue, Rhodamine and Rosamiline.  The lotion may also contain one or more wetting agents, e.g. a polyoxyalkylene sorbitan manolaurate or an alkylaryl sulphonate, and a perfume and may be applied to the hair from a plastic &#34;squeeze&#34; bottle.
PURPOSE:To obtain a novel antibiotic substance capable of exhibiting antimicrobial activity against Gram-positive and Gram-negative bacteria, by separating and collecting the novel antibiotic substance from a microorganism belonging to the genus actinomycetous genus Streptomyces. CONSTITUTION:A species of the genus Streptomyces having the ability to produce an antibiotic substance RK-1061A, RK-1061B and RK-1061C, e.g. Streptomyces sp. RK-1061 (FERM-P No.8278), is cultivated. The cultivation is carried out in an ordinary culture medium containing a carbon source, nitrogen source, etc. by the spinner culture method with aeration, etc. to afford the aimed novel antibiotic substance from the cultivation filtrate and extract of microbial cells. The resultant substance is purified by chromatography, etc. in combination and then subjected to high-speed liquid chromatography and separated into the substance RK-1061A, RK-1061B and RK-1061C. The substance has the following properties; White powder, decomposed at &gt;=190 deg.C and readily soluble in water, etc.
A  papaver  from  rhoeas &#39; cell and tissue stain is formulated incorporating a new one bioflavonoid which specifically stains the nucleus for microscopic evaluation in histopathology, microbiology and cytology. It appears to be an alternative to hematoxylin for routine usage. Biochemical name of this compound is hydroxy-7-methoxy-2-(4-methoxy-3-(((2R,3R,4S,5S,6R)-3.4.5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3.4.5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2- yl)oxy)phenyl)-4H-chromen-4-one. NMR analysis shows the biochemical structure of molecule is a bioflavonoid. (FIG.  4,5 ) Molecule within  Papaver rhoeas  along with the synergistic and other molecules penetrates the biologic and nonbiologic samples. Combining with the other synergistic mechanisms the stain formula is prepared. The amount and type of Mordant and pH are the parameters that affect the quality and timing of the staining results.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a fat metabolism-improving food composition obtained by utilizing bean curd refuse comprising by-products generated when producing bean curd, soy milk or the like, or oily food residue generated after squeezing oil so as to contribute reuse of waste products, possibly exhibiting more remarkable fat metabolism improving function: and to provide food containing the composition.  &lt;P&gt;SOLUTION: The fat metabolism-improving food composition contains 10-50 mass% of dry bean curd refuse, and fish oil. The content of EPA (eicosapentaenoic acid) and/or DHA (docosahexaenoic acid) in the fish oil is within 0.5-5.0 mass% of the dry bean curd refuse. The fish oil is preferably contained in the bean curd refuse within 1-20 mass%. The fish oil preferably contains EPA and/or DHA at 30-50 mass% in total.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
In vitromethod for inhibiting simultaneously the expression of several target genes (I) that encode proteins of interest (II), especially tumorigenic proteins. It comprises contacting (I) with at least one ligand (III) that recognizes a common target in (I) and induces cutting by topoisomerase; binding (III) to (I); analyzing cutting of the genes and determining inhibition of expression. Independent claims are also included for the following: (1) compound (A) able to form a ternary complex and comprising a DNA ligand specific for (I), a linker and an inhibitor (X) of topoisomerase I; and (2) compound (B) that is the conjugate of a triplex-forming oligonucleotide (OFT) and (X), able to induce cutting of DNA and directing cutting near each oligopyrimidine:oligopurine sequence in (I) that contains 2-30 pairs, with a cutting site of (X) 3&#39; to the triplex on the oligopyrimidine strand of the target. ACTIVITY : Cytostatic; Virucide; Anti-HIV. No details of tests for these activities are given. MECHANISM OF ACTION : Inhibiting expression of anti-apoptosis genes or genes that regulate the cell cycle.
PURPOSE:To provide a carcinostatic assistant composed of extract of KAMI- SHOYOSAN or TOKAKU-SHOKITO which is a compounded Chinese herb drug for women&#39;s dizziness, having mitigated side effect of cisplatin such as renal disorder and useful as an assistant to promote effective and safe remedying effect of cisplatin. CONSTITUTION:The objective carcinostatic assistant for cisplatin is composed of an extract of KAMI-SHOYOSAN [composed of 3.0pts.(wt.) each of TOKI (root of Angelica acutiloba), SHAKUYAKU (root of Paeonia albiflora), BYAKUJUTSU (rhizome of Atractylodes japonica) and SAIKO (root of Bupleurum falcatum), 2.0pts. each of BOTANPI (root bark of Paeonia moutan) and SANSHISHI (fruit of Gardenia jasmioides), 1.5-2pts. of KANZO (root of Glycyrrhiza glabra var. glandulifera), 0.5-2pts. of SHOKYO (rhizome of Zingiber officinale) and 1.0pt. of HAKKA (leaf of Mentha arvensis)] or TOKAKU-SHOKITO [composed of 5pts. of TONIN (stone of Prunus persica), 4pts. of KEIHI (bark of Cinnamomum cassia), 1-3pts. of DAIO (rhizome of Rheum palmatum), 1pt. of dried sodium sulfate and 1.5pts. of KANZO]. The extract suppresses the increase of BUN value and creatinine value caused by cisplatin. It is preferably administered continuously even in the pausing period of the cisplatin administration.
The present invention relates to a mixture which comprises three antioxidants: vitamin C, vitamin E and melatonine. The mixture forms a novel anti-biological cell free radical oxidation injury mixture. The novel anti-biological cell free radical oxidation injury mixture can be used as a novel high-efficiency anti-biological cell free radical oxidation injury substance to be applied to various fields which are relevant to biological cell free radical oxidation injury. The fields are used for preventing and treating diseases which are relevant to cell free radical oxidation injury, such as retrograde affection (presenile dementia, Parkinson&#39;s diseases and cerebrosclerosis) in the nervous system, apoplexy, cardiovascular diseases (angina pectoris, myocardial ischemia and coronary atherosclerosis), tumour, cataract, elasticity descend of the skin, and wrinkles of the skin. The mixture is also used as supporting an auxiliary medicament for operation on the heart, treatment of dissolving thrombus, the field of organ transplantation, nursing care of the skin, and radiotherapy and chemotherapy of tumour. The effect of the mixture is much higher than that of any ingredient which is singly used in the mixture. Simultaneously, the defects of a peroxidation phenomenon caused by the phenomenon that an antioxidant is singly used, etc. are overcome.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop a vaccine candidate causing immune response specific to H. influenzae and controllable.  &lt;P&gt;SOLUTION: The chimeric protein contains a part of Pi1A and a part of LB1 peptide. The chimeric protein contains the Pi1A modified so as to present a B-cell epitope of the LB1 peptide. The vaccine composition contains one or more of the chimeric proteins. The method for causing the immune response by using the chimeric protein is also provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington&#39;s disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop an inhibitor of JAK, JNK, GSK, SYK, and CDK protein kinases.  &lt;P&gt;SOLUTION: The invention provides a compound of formula I or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions containing the compound and a method for utilizing the compounds and the compositions in the treatment of various protein kinase-mediated disorders. The compounds and its pharmaceutically acceptable compositions are effective as inhibitors of JAK-3, JNK-3, CDK-2, SYK, and GSK-3 protein kinases. The composition contains the compound of formula I, and a pharmaceutically acceptable carrier, adjuvant or vehicle.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Tablets contg. undegraded carrageenin Title compns showing an increased anti peptic activity over degraded carrageenin and having a good disintegration time are prepd by granulating undegraded carrageenin with an aq or alcoholic soln adding a disintegrating agent esp micro crystalline cellulose and forming the tablets. Strong electrolytes e.g. NaCl, KCl, MgCl2 or Na2SO4 reduce to amount of cellulose req&#39;d without affecting the disintegration. The tablets may be coated. Disintegration time is 5-10 mins.
A formulation of green porphyrins as described in Fig.1A to 1F as an effective photoactive agent to improve visual acuity upon irradiation with light absorbed by the photoactive agent after administration and localisation of the agent in the eye of a human subject. The side groups are defined as follows for Fig.1A to 1F: R1 and R2 is selected from C2-6carbalkoxyl, C1-6alkyl, C6-10arylsulfonyl, CN or -CONR5CO; R5 is selected from C6-10aryl or C1-6alkyl; R3 is selected from carboxyl, C2-6carboxyalkyl or a salt, amide, ester or acyl hydrazone or C1-6alkyl; R4 is selected from -CH=CH2 or -CH(OR4&#39;)CH3; R4&#39; is selected from H, or C1-6alkyl optional substituted with a hydrophilic substituent. Photodynamic therapy (PDT) of conditions of the eye, especially those conditions characterised by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects. The formulation includes any pharmaceutical excipient, in combination with a photoactive agent. The preferred pharmaceutical excipient are liposomes, as the formulation is able to selectively deliver the green porphyrins to the desired site. The irradiation occurs at an irradiance of 600 mW/cm2 to provide a total fluence of 50 J/cm2 to 150 J/cm2.